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Sustained virologic responseEgypt has the highest prevalence of hepatitis C virus (HCV) worldwide. Currently, combined
pegylated interferon and ribavirin therapy are the standard treatment. The biological activity
of interferon (IFN) is mediated by the induction of intracellular antiviral proteins, such as
20–50 oligoadenylate synthetase, and dsRNA-activated protein kinase. IFN-inducible double-
stranded RNA-activated protein kinase (PKR) is thought to play a key antiviral role against
HCV. Some studies observed that PKR expression was higher in sustained viral responders
compared with the non-responders. The PKR is considered as antiviral toward HCV and
responsible for IFN’s effect against HCV while others have showed that, there were kinetic
results indicate that HCV infection is not altered by reduced levels of PKR, indicating that
HCV is resistant to the translational inhibitory effects of the phosphorylated forms of PKR.
This study was conducted on 50 consecutive patients with chronic HCV infection (CHC) and
20 healthy controls. All the patients were subjected to clinical and laboratory assessment,
abdominal ultrasound, and liver biopsy. Determination of PKR gene quantity by using a real
time PCR was done at the baseline and at the end of treatment for all patients and controls.
Pre-treatment levels of protein kinase gene were signiﬁcantly higher in responders in compari-
son with non-responders (P< 0.001). It was found that 97.06% of patients who were respond-
ing to treatment had the expression of protein kinase gene greater than 26 cycle threshold.
ª 2014 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Chronic liver disease and hepatocellular carcinoma are major
worldwide public health problems in countries with endemi-
cally high levels of viral hepatitis (B and C) [1]. Chronic hepa-
titis C virus (HCV) infection affects more than 170 million
persons worldwide and responsible for the development of
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considered the most common etiology of chronic liver disease
(CLD) in Egypt, where prevalence of antibodies to HCV (anti-
HCV) is approximately 10-fold greater than in the United
States and Europe [3]. The prevalence of genotype 4 as the
main HCV genotype with different subtypes as well as differ-
ent virological, biochemical and histopathological responses
to treatment in comparison to the other well-known isolated
ﬁve genotypes; made it an important and interesting task for
many researchers to study the interaction between the viral
genome and the anti-viral preparations specially IFN which
has many preparations and has both an anti-viral as well as
an immune-modulator role in combating the virus [4]. As a re-
sult of the continuing research for better medications; the
development of new and efﬁcient medications remained an
important concern of many research institutions in the ﬁeld
of hepatology. Interferon alpha (IFN alpha) has been widely
used as therapy for chronic hepatitis C. The attachment of
an inert Poly Ethylene Glycol (PEG) molecule to the standard
IFN had resulted in the production of long acting IFN which
was named Pegylated Interferon (PEG-IFN). Standard treat-
ment with pegylated alpha IFN in combination with the nucle-
oside analogue ribavirin leads to a sustained virologic response
in approximately half of the patients [2]. Although the efﬁcacy
of antiviral therapy in chronic hepatitis C has improved since
interferon was introduced, nonresponse to this therapy re-
mains common. Several factors have been shown to inﬂuence
response [5]. The biological activity of interferon (IFN) is med-
iated by the induction of intracellular antiviral proteins, such
as 20–50 oligoadenylate synthetase, dsRNA-activated protein
kinase and MxA protein. Interferon (IFN)-inducible double-
stranded RNA-activated protein kinase (PKR) is thought to
play a key antiviral role against hepatitis C virus (HCV) [6].
Double-stranded RNA-activated protein kinase (PKR) plays
a role in cell defense against virus infection. Ribavirin was able
to up-regulate the levels of phosphorylated PKR and phos-
phorylated eIF2 alpha, leading to suppression of HCV-RNA
replication. The molecular mechanisms that regulate PKR
function in normally dividing cells are largely unknown.
PKR is implicated in controlling HCV replication and mediat-
ing interferon- induced antiviral state against HCV replication
[7]. Some viruses including hepatitis viruses can evolve various
devices to down-regulate PKR and overcome the host defense
mechanism against virus replication [8]. In addition to PKR,
PKR-independent antiviral pathways are believed to play
important roles in cellular defense against HCV replication [9].
Patients and methods
This study was a prospective study. The sample size was 70
subjects divided into two groups. Group I consists of 20
healthy volunteer subjects who matched age and sex with pa-
tients. With men-to-women ratio of 11/9, their age ranged
from 18 to 47 years. Group II consists of 50 naı¨ve patients
to be treated with PEG-IFN-a2b, at a dose of 1.5 lg/kg subcu-
taneously every week plus ribavirin at a dose of 1000–1200 mg/
day, according to the patient’s body weight, for 48 weeks, with
men-to-women ratio of 34/16; their age ranged from 18 to
60 years. Strict inclusion criteria were set to nullify the effect
of confounding variables and further minimize selection bias.
The inclusion criteria are adult men or women (18–60 yearsold) with proven chronic hepatitis C genotype 4, elevation of
aspartate aminotransferase and alanine aminotransferase lev-
els, positive serum HCV-RNA by quantitative PCR, naive pa-
tients (not previously treated with any antiviral drugs
including IFN, ribavirin, thymosin and lamivudine). The
exclusion criteria are decompensated liver disease, histological
evidence of hepatic cirrhosis diagnosed by hepatic histopathol-
ogy, pregnant or nursing female, concomitant hepatic schisto-
somal infection (excluded by rectal snip and pathologically),
alcohol intake, other etiologies of chronic hepatitis (e.g. auto-
immune, hepatitis B virus infection and drug-induced liver in-
jury) and presence of any chronic systemic illness.
All the patients were subjected to clinical assessment.
Height and weight were determined at baseline and body mass
index (BMI) was calculated as weight in kilograms divided by
height in meters squared (weight in kilograms/height in
meters).Laboratory investigations
Liver enzymes including ALT (alanine aminotransferase), AST
(aspartate aminotransferase), serum albumin (Alb), serum bil-
irubin including total bilirubin (T BIL), prothrombin time
(PT), complete blood count (CBC), lipid proﬁle and fasting
blood sugar were assayed using Beckman CX4 chemistry ana-
lyzer (NY, USA, supplied by the Eastern Co. For Eng. &
Trade-Giza, Egypt). Alpha fetoprotein (AFP) and viral status
were measured using Abbott, Axyam (USA, Supplied by Al
Kamal Company Cairo, Egypt).Molecular tests
Quantitative detection of HCV-RNA in serum by real-time
PCR and RNA extraction from lymphocytes for quantitative
gene expression of PKR by real-time PCR were performed
for all patients and controls.
Quantitation of hepatitis C virus-RNA in serum by real-
time PCR RNA was extracted from serum and reverse trans-
criptase polymerase chain reaction was performed initially
and repeated periodically throughout the period of the study
(3, 6 and 12 months). HCV-RNA was quantitated in all pa-
tients’ serum using real-time PCR (Stratagene, LaJolla, CA,
USA).
According to quantitative PCR value, we can determine the
level of viremia and the response to the treatment.
Quantiﬁcation of PKR gene expression by real-time PCR
PKR gene expression was performed at the beginning of treat-
ment and repeated after 3 months during the study.
Preparation of PBMCs obtained from peripheral blood of
all patients and controls were isolated by Ficoll density centri-
fugation and sedimentation. RNA was extracted from PBMCs
cells using QIAamp viral RNA extraction kit (QIAGEN
GmbH, Hilden, Germany). Quantiﬁcation of PKR gene was
performed using TaqMan Gene Expression (Applied Biosys-
tems Inc, Foster City, CA, USA). B-actin was used as house-
keeping gene (endogenous reference cDNA). Fractional
threshold cycles (CT) were expressing the initial concentration
of target sequence. Relative mRNA quantiﬁcation was calcu-
lated using the arithmetic formula 2Dct where, CT was the dif-
ference between the CT of a given target cDNA and an
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amount of the target normalized to an endogenous reference.
Statistical analysis
Statistical analysis was performed using the statistical package
for social sciences (SPSS, USA). Data are expressed as
means ± standard error. The Mann–Whitney, Wilcoxon
Signed Ranks, Chi-square–Fisher’s Exact tests were used for
the comparisons of proportions. A p< 0.05 was considered
signiﬁcant.
Informed consent was obtained from all participating sub-
jects before the study. The study protocol was approved by the
ethics committee of the National Hepatology and Tropical
Medicine Institute, Cairo, Egypt, and conformed to the ethical
guidelines of the 1975 Helsinki Declaration. Its Serial Number
was: 7-2009 in date 22-8-2009.Table 1 Comparison between HCV patients before IFN treatment
Control (gpI) HCV patie
P25 Median P75 P25
AST 26.00 31.00 37.50 48.50
ALT 26.00 29.00 35.75 43.50
T BIL 0.60 0.80 0.90 0.80
D BIL 0.10 0.10 0.20 0.20
Alb 3.63 3.85 4.00 3.60
Glucose 90.75 99.50 111.50 90.00
AFP 4.00 6.00 7.15 5.00
PT 11.00 11.00 12.00 90.00
TSH 1.93 2.75 3.78 3.10
Creatinine 0.83 1.00 1.10 0.90
PKR gene 211 214 215 24
Hb 10.25 11.00 13.75 10.00
P: Percentiles, ALT: alanine aminotransferase; AST: aspartate aminotra
alpha fetoprotein, TSH: thyroid stimulating hormone, PKR: Protein kin
Mann–Whitney test, is used as to compare between the two groups.
Z: It is a value on horizontal axis of standard normal distribution curve, P
Table 2 Comparison between all biochemical parameters in HCV p
HCV patients
Before treatment (gpII) A
P25 Median P75 P25
AST 48.50 60.00 70.00 30.00
ALT 43.50 60.00 68.50 30.00
T BIL 0.80 1.00 1.20 0.70
D BIL 0.20 .20 0.30 0.10
Alb 3.60 3.80 4.00 3.40
Glucose 90.00 100.0 103.5 90.00
AFP 5.00 8.00 12.00 7.75
PT 90.00 90.00 100.0 87.00
TSH 3.10 3.60 4.00 3.00
Fibrosis 3.00 3.00 4.00 2.00
Creatinine 0.90 1.00 1.00 0.90
PKR 24 29 211 22
Hb 10.00 12.00 13.00 9.00
P: Percentiles, Wilcoxon Signed Ranks test is used to compare between
transferase; AST: aspartate aminotransferase, TBil: Total bilirubin, Hb
stimulating hormone, PKR: Protein kinase gene. Z: it is a value on horiz
high signiﬁcant, S: signiﬁcant, NS: non-signiﬁcant.Results
The median value of PKR gene expression in control and
group II was 214 and 29, respectively. There was a statistically
signiﬁcant difference between group II and controls
(P< 0.0001) (Mann–Whitney test). Cases (group II) showed
signiﬁcantly higher level of AST, ALT, Tbil, AFP, PT, Tsh
when compared to control group (P< 0.05) Table 1. The
median level of PKR gene expression at baseline was 29, and
after treatment, it was 215. There was a statistically signiﬁcant
increase in PKR gene expression after treatment (Wilcoxon
Signed Ranks test) (P< 0.0001) Table 2. Table 3 showed that,
there was no statistically signiﬁcant difference (P> 0.05) be-
tween male and female or obese and non-obese patients
regarding PKR gene expression. Non-obese patients showed
signiﬁcantly higher rate of response than obese (P< 0.05)
while regarding gender, there was no signiﬁcant difference(gpII) and controls (gpI).
nts Before treatment (gpII) Z P-value Sig.
Median P75
60.00 70.00 5.57 <0.0001 HS
60.00 68.50 6.13 <0.0001 HS
1.00 1.20 3.48 0.001 S
0.20 0.30 3.76 <0.0001 HS
3.80 4.00 0.53 0.59 NS
100.00 103.50 1.02 0.30 NS
8.00 12.00 2.59 0.009 S
90.00 100.00 5.06 <0.0001 HS
3.60 4.00 3.21 0.001 S
1.00 1.00 0.61 0.544 NS
29 211 4.30 <0.0001 HS
12.00 13.00 0.47 0.63 NS
nsferase, TBil: total bilirubin, Hb: hemoglobin, Alb: albumin, AFP:
ase gene.
: probability, HS: high signiﬁcant, S: signiﬁcant, NS: non-signiﬁcant.
atients before and after IFN treatment.
Z P-value Sig.
fter treatment (gpIII)
Median P75
38.50 60.00 4.65 <0.0001 HS
35.50 40.00 5.73 <0.0001 HS
0.80 1.00 2.13 0.03 S
0.20 .20 1.87 0.06 NS
3.90 4.00 1.66 0.10 NS
100.0 130.00 2.46 0.01 S
9.00 10.00 .76 0.45 NS
90.00 92.00 2.08 0.04 S
4.00 5.00 2.53 0.01 S
2.00 4.00 1.87 0.06 NS
1.00 1.20 2.22 0.03 S
215 216 6.12 <0.0001 HS
10.50 11.00 4.63 <0.0001 HS
the HCV patients before and after treatment. ALT: alanine amino-
: hemoglobin, Alb: albumin, AFP: alpha fetoprotein, TSH: thyroid
ontal axis of standard normal distribution curve, P: probability, HS:
Table 3 Comparison between male and female and obesity regarding PKR gene expression.
Before treatment Male Female Z P-value
P25 Median P75 P25 Median P75
PKR 24 28 211 23 210 211 0.20 0.84
Obese Non-obese
PKR 23 26 211 28 210 211 1.72 0.09
P = Percentiles, Mann–Whitney test is used to compare between male and female before treatment and between obese and non-obese before
treatment regarding PKR.
The unit of PKR gene was: CT (cycle threshold), and equation for calculation of PKR gene expression was: 2Dct cycle threshold.
Table 4 Comparison between responders and non-responders.
Group P-value
No response Response
N % N %
Load of viremia Low 3 21.4 11 78.6 >0.05
Moderate 7 30.4 16 69.6
High 6 46.2 7 53.8
BMI Non-obese 3 11.5 23 88.5 0.002*
Obese 13 54.2 11 45.8
Sex Female 4 25.0 12 75.0 0.53
Male 12 35.3 22 64.7
* Chi-square test–Fisher’s Exact test.
Table 5 Comparison between HCV patients who are responders and non-responders to the treatment with INF.
No response (16) Response (34) Z P-value Sig.
P25 Median P75 P25 Median P75
Age* (mean ± SD) ±7.87 40.50 ±8.30 40.35 0.06 0.95 NS
AST 60.00 69.00 90.00 45.50 50.00 68.50 3.15 0.002 S
Alt 47.00 57.00 67.50 40.00 60.00 68.50 0.40 0.69 NS
T BIL 0.80 1.00 1.43 0.80 1.00 1.20 0.22 0.83 NS
D BIL 0.20 .20 0.30 0.20 .20 .25 0.79 0.43 NS
Alb 3.53 3.60 4.00 3.60 3.80 4.00 0.95 0.34 NS
Glucose 81.25 90.00 103.75 90.00 100.00 103.50 0.97 0.33 NS
AFP 6.00 9.00 14.00 4.00 8.00 12.00 0.47 0.64 NS
PT 90.00 90.00 97.50 90.00 95.00 100.00 1.23 0.22 NS
TSH 3.00 3.40 4.00 3.45 3.70 4.00 1.63 0.10 NS
Fibrosis 3.00 3.00 4.00 3.00 3.00 4.00 0.65 0.51 NS
HIA 5.25 6.00 7.00 5.00 6.00 6.50 1.64 0.10 NS
Creatinine 0.90 1.00 1.15 0.90 0.90 1.00 0.99 0.32 NS
PKR 24 29 211 22 215 216 5.38 <0.0001 HS
Hb 12.00 13.00 13.75 10.00 12.00 13.00 1.54 0.12 NS
Mann–Whitney test, P = Percentiles. ALT: alanine aminotransferase; AST: aspartate aminotransferase, TBil: Total bilirubin, Hb: hemoglobin,
Alb: albumin, AFP: alpha fetoprotein, TSH: thyroid stimulating hormone, PKR: Protein kinase gene .
Z: It is a value on horizontal axis of standard normal distribution curve, P: probability, HS: high signiﬁcant, S: signiﬁcant, NS: non-signiﬁcant.
* Unpaired t test
120 A.A. Mohamed et al.between male and female cases in response to IFN treatment,
also there was no signiﬁcant difference regarding level of vire-
mia and response to interferon treatment (P> 0.05) Table 4.
At the end of the study, patients were subdivided into respond-
ers and non-responders to treatment. Table 5 shows thatresponders had signiﬁcantly higher initial PKR gene expres-
sion (215) compared to non-responders (29) (p< 0.0001).
Responders showed a higher percentage of cases with initial
PKR> 26, the number of responder cases was 34(68%) vs
16(32%) in non-responders Table 6. Receiver operating
Table 6 The relationship between the response to IFN treatment and initial PKR gene expression.
Response No response Total P-value
N % N %
PKR <26 1 6.25 15 93.75 16 <0.001*
P26 33 97.06 1 2.94 34
Patients who had the expression of protein kinase gene greater than or equal to 26 CT showed higher responding percentile to the treatment
compared to those who had the expression of protein kinase gene less than 26 CT. So 26 CT was considered the best cut off value to detect the
response.
* Fisher’s Exact test.
1 - Specificity
1.00.80.60.40.20.0
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ns
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ROC Curve
Fig. 1 Receiver operating characteristic (ROC) curve to deﬁne
the best cutoff value to PKR expression to detect response.
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off point. A value of 26 was the best cut-off point to predict
response. So, PKR levels of 26 provided a sensitivity of 97%,
a speciﬁcity of 94% and a positive predictive value of 97%,
negative predictive value of 94% with area under the curve
0.97 and P value less than 0.0001. According to these results,
PKR gene had a good predictive ability.
Discussion
HCV infects 2–3% of the world population. A majority of in-
fected people fail to clear the virus and are at risk for develop-
ing serious liver complications [10]. It was found that HCV
accounts for about 20% of cases with acute hepatitis, 70%
with chronic hepatitis, 40% with cirrhosis, 60% with hepato-
cellular carcinoma and 15–30% with liver transplantation
[11]. Opportunities for prospective studies are rare becausemost infections are asymptomatic [12]. The effectiveness of
therapy for patients with chronic hepatitis C has greatly im-
proved in the last few years, [13]. PKR is well-recognized as
an important effector of the antiviral response through its abil-
ity to arrest protein synthesis and its importance is highlighted
by the number of viral and cellular products that are able to
abrogate or modulate its action [14]. In the case of HCV, some
viral proteins such as NS5A and a cytosolic soluble form of E2
were reported to interact with PKR, and were proposed to be
viral inhibitors of the antiviral action of PKR [15]. Gale et al.
[16], had a direct proof that NS5A interacts with and inhibits
the IFN induced protein kinase, PKR. Importantly, they
found that the ISDR was required for NS5A interaction with
PKR and repression of PKR activity. These data thus provide
the ﬁrst evidence for the molecular mechanisms underlying
HCV resistance to IFN therapy and agree with our results
which indicate the effective role of PKR gene against Hepatitis
C virus infection in our responder patients who were higher
comparing with non-responders regarding to PKR gene
expression value.
It has been proposed that mutations in the RNA-dependent
protein kinase (PKR) binding domain (PKRBD) within the
HCV viral NS5A gene disrupt NS5A-PKR interactions and
are important factors contributing to IFN sensitivity and
repression of viral function [17]. This present study showed
that, there was a statistically signiﬁcant increase in PKR gene
expression in group I (control) when compared with patients
(group II) (CHC) at P< 0.0001 Table 1. This may be due to
the ability of HCV virus to counteract the PKR gene response
to viral infection by encoding proteins that inhibit PKR gene
function. There was a statistically signiﬁcant difference
(P< 0.0001) between responders and non-responders as re-
gards the PKR gene expression 215, 29, respectively using
Mann–Whitney test. Responders showed a statistically higher
value of PKR compared to non-responders Table 5. These re-
sults were in agreement with some studies which observed that
PKR expression in response to PEG-IFN was higher in sus-
tained viral responders compared with the non-responders
[18]. It is considered as antiviral agent towards HCV and
responsible for IFN’s effect against HCV [6] The results of
Chang et al. [19] suggest that PKR is inhibitory to HCV
RNA replication which is in agreement with our results indi-
cating that PKR gene high expression leads to high chance
for HCV patient response to interferon treatment with
ribavirin.
However, the present results disagreed with those of Gar-
aigorta and Chisari [20] who have showed that, their kinetic re-
sults indicate that HCV infection is not altered by reduced
122 A.A. Mohamed et al.levels of PKR, indicating that HCV is resistant to the transla-
tional inhibitory effects of the phosphorylated forms of PKR
and eIF2a that it induces during infection.
In our study we found that, there was no signiﬁcant differ-
ence between responders and non-responders (P> 0.05)
regarding alanine transaminase (ALT), albumin (Alb), creati-
nine, hemoglobin and prothrombin time Table 5 which was
in agreement with Ogawa et al. [21]. Regarding the gender, Ak-
ram et al. [22] found signiﬁcantly high SVR rates at p value
(p< 0.01) in male patients when compared with female pa-
tients, while in another study, they found that, female sex de-
crease the risk of disease progression [23]. On the contrary, we
found no signiﬁcant difference regarding gender in the differ-
ent responding groups to interferon treatment Table 4.
Regarding the comparison between responders and non-
responders, George et al. [24] found that there was no signiﬁ-
cant difference between ﬁrst and last collected samples in the
mean alanine transaminase (ALT), aspartate transaminase
(AST), total bilirubin (TBIL), hemoglobin (Hb) which was in
contrary with our study in Table 2 where we found that for
ALT (p< 0.0001), AST (p< 0.0001), T BIL (p= 0.03), and
Hb (p< 0.0001). However their results agreed with our results
in ﬁnding that there was no signiﬁcant difference in albumin
(p= 0.10). Our results indicated that, there was signiﬁcant dif-
ference in BMI among responders and non-responders (the
number of responder non-obese subjects were 23 and obese
subjects were 11 while the non-responder non-obese subjects
were only 3 and obese subjects were 13) which was in agree-
ment with Ascione et al. [25], who reported that, overweight
and obesity were considered from the pretreatment factors
causing a decrease in the sustained virological response
(SVR) Table 4.
In this study, it was found that PKR gene expression is per-
fect and reliable to predict (at P< 0.0001), where the receiver
operating characteristic (ROC) curve is plotted to determine
the best cut-off value of PKR gene expression which is 96 with
sensitivity of 96%, speciﬁcity 96%, diagnostic accuracy of
96% and area under the curve (AUC) is 99%.Conclusion
PKR gene expression is a sensitive biological marker for viral
replication. These results highlight the importance of the detec-
tion of PKR gene expression at the start of therapy as a pre-
dictable factor for assessing the likelihood of HCV genotype
4 SVR for treatment with IFN-a2 in combination with
ribavirin.Conﬂict of interest
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